2018 speakers include… - proteins congress · • jens frauenfeld, chief executive officer,...

For booking details & registration fees please refer to the last page or visit: http://www.proteins-congress.com/marketing

Protein Purification Protein Technology Platforms Protein Structure Prediction

Custom Protein Production Custom Antibody Production Immunogenicity Assessment

Display Technologies Process Development Computational Chemistry

Recombinant Antibody Antibody Analysis Protein Identification

Discover New Solutions Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

Protein Structure Protein Expression Protein Engineering

Antibody Technology Antibody Discovery Antibody Therapies

Manufacturing Science Analytical Development Discovery Therapeutics

Biologics Development Biologics Profiling Biological Sciences

Benefits to Attending

✓ Hear from and meet with the key innovators in proteins & antibodies. 2018 attendees include: Chief Medical

Officer, Merck & Co., Inc.; Senior Vice President, Teva Pharmaceuticals, Vice President, Johnson & Johnson

✓ Discover collaborative solutions to protein engineering,

designs and selection. Our highly established event will

bring together key opinion leaders to discuss protein half-life

extension updates, novel conjugation strategies and

computational tools

✓ New to 2018! Discuss the latest innovations in

biotherapeutics: manufacturing, chemistry, analytics

and control. Topics to be covered include: characterising

biotherapeutics, developability and manufacturing updates

✓ Learn more about antibody engineering, design &

development. Discuss new concepts for characterising

antibodies and innovative design approaches

✓ Unparalleled networking opportunities. The two-day

congress offers dedicated networking breaks creating an

interactive platform for scientific discussions and 1-2-1

meetings. The exhibition hall and poster presentation

spaces offer a relaxed and professional environment for

scientific discussion

✓ Co-located with the highly anticipated 5th Annual

Biosimilars & Biobetters Congress and 5th Annual

Peptides Congress

Meet Senior Decision Makers 450 senior attendees from leading pharmaceutical, biopharmaceutical, academics, CRO and solution provider companies will be attending. Meet Senior VPs, Directors, & Managers with the following job titles:

Day 1 Stream 1 – Protein Engineering, Design & Selection • Novel approaches to protein engineering

• Novel protein conjugation strategies

• Improving protein half-life extension, potency & selectivity

• Advanced computational tools for engineering proteins

Day 1 Stream 2 – Biotherapeutics: Manufacturing, Chemistry, Analytics and Control • Overcoming the challenges of characterising biotherapeutics

• Understanding protein aggregation

• Testing protein stability

• Formulations to increase stability

• Novel technologies & techniques to analyse biotherapeutics

• Developability of biotherapeutics

Day 2 Stream 1 – Antibody Engineering, Design & Development • Advancing to the clinic: antibody drug conjugates

• Innovative design and engineering approaches

• New concepts for developing bispecific antibodies

• Advanced antibody structures and dynamics

• Advances in the generation and characterisation of antibodies

Day 2 Stream 2 – Cloning, Expression, Purification & Analytics • Novel strategies to express proteins

• Overcoming the expression challenges of difficult to express proteins

• Updates in protein purification and analytics

• Updates in cryo-em techniques

• Detection of antibodies by LC/MS

• Cell line development and cell line engineering

Day 2 Stream 3 – Protein & Antibody Biotherapeutics

• Fusion protein therapeutics • New targets & new indications for protein biotherapeutics

• Accelerating antibody discovery & optimisation: o Bispecific antibodies o Monoclonal antibodies o Antibody drug conjugates

• Cutting edge technologies for antibody discovery

• Therapeutic antibody development

• Targeting immune checkpoints

• Immunogenicity of therapeutic antibodies: prediction and risk mitigation

2018 Speakers Include…

Roy Baynes Katarina Radošević Sharon McGonigle

MSD Sanofi R&D Eisai

FREE WEBINARS 2018:

• Protein & Antibody Biotherapeutics – Manufacturing & Developability Assessment – 16th January 2018. Register here.

• Antibody Biotherapeutics: Current Technologies And Recent Therapeutic Success – 24th January 2018. Register here.

Including 5+ Think Tank Round Table Discussions

http://www.proteins-congress.com/marketing

https://www.proteins-congress.com/free-proteins-live-webinar-i/

https://www.proteins-congress.com/free-webinar-ii/

For more information please contact [email protected]

If you’re on Twitter, make sure to follow us @proteincongress and join the Congress conversation using #Proteins2018

2018 Confirmed Speakers Include:

• Roy Baynes, Chief Medical Officer, Senior Vice President and Head of Global Clinical Development, MSD

• David Mantus, Chief Development Officer, Arsanis

• Jens Frauenfeld, Chief Executive Officer, Salipro Biotech AB

• Yanay Ofran, Chief Executive Officer & Founder, Biolojic Design and Professor of Biophysics and Computational Biology, Bar-Ilan University

• Steffen Nock, Senior Vice President (Global Biologics Head), Teva Pharmaceuticals

• Syd Johnson, Vice President, Antibody Engineering, Macrogenics

• Annelise Vuidepot, Vice President, Head of Oncology Pipeline and Research, Immunocore

• Sanjaya Singh, Vice President and Head, Biotherapeutics, Johnson & Johnson

• Vincent Ling, Senior Director, Takeda Pharmaceuticals

• Hari Hariharan, Senior Director, Biotherapeutics, Celgene

• Angela Norton, Senior Director and Head, Protein & Antibody Engineering, Shire Pharmaceuticals

• Zhulun Wang, Executive Director, Research, Amgen

• Michelle Morrow, Director, Preclinical Translational Pharmacology, F-Star Biotechnology

• Sujata Sharma, Director, Protein Science, Merck & Co., Inc.

• Emma Harding, Director, Head of Molecular Design and Engineering, GlaxoSmithKline

• Ai Ching Lim, Director, Research, Amgen

• Andy Hooker, Director of Pharmaceutical Sciences, Ipsen Bioinnovation Ltd

• Kenneth Walker, Director of Research, Biologics, Amgen

• Claire Dobson, Associate Director, Antibody Discovery and Protein Expression, MedImmune

• Yung-Hsiang Kao, Associate Director and Principal Scientist, Genentech

• W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie

• Patrick Garidel, Associate Director, Protein Chemistry, Boehringer Ingelheim

• Stefan Weigand, Global Head of Large Molecule Research, F.Hoffmann-La Roche

• Katarina Radošević, Global Head Biologics Research, Sanofi R&D

• Thorsten Lorenz, Group Head Developability Assessment 1, Novartis

• David Gervais, Head of Product Development, Porton Biopharma

• Alexey Rak, Head, BioStructure & Biophysics, Sanofi

• Darko Skegro, Senior Team Leader, Novartis

• Sharon McGonigle, Senior Principal Scientist, Eisai

• Ramu Sadhukhan, Principal Research Scientist, AbbVie

• Michael Chin, Senior Principal Scientist and Associate Research Fellow, Pfizer

• Tina Møller Tagmose, Principal Scientist, Novo Nordisk A/S

• Jane Seagal, Principal Research Scientist, AbbVie

• Sepideh Afshar, Principal Research Scientist, Department of Protein Engineering, Eli Lilly & Company

• Sally Fischer, Principal Scientist and Group Leader, Genentech

• Carsten Behrens, Principal Scientist, Novo Nordisk A/S

• Berthold Boedeker, Chief Scientist and Project Coordination, Bayer AG

• Ren Liu, Team Leader and Associate Principal Scientist, Merck & Co., Inc.

• Pallavi Tawde, Single B Cell Cloning Platform Leader, Bristol-Myers Squibb

• Dorina Saro, Senior Research Scientist, Johnson & Johnson

• Christopher Lloyds, Senior Scientist, Senior Scientist, Protein Engineering, MedImmune

• Kaimeng Zhou, Analytical Team Lead, Bristol-Myers Squibb

• Christian Bernloehr, Project Leader, Molecular Biology Department, Boehringer Ingelheim

• Zhi Chen, Senior Scientist, Molecular and Analytical Development, Global Manufacturing & Supply, Bristol-Myers Squibb

• Kerstin Otte, Professor, University of Applied Sciences Biberach

• Jon Sayers, Professor of Functional Genomics, University of Sheffield

• Alexander Golovanov, Senior Lecturer and Principal Investigator, Manchester Institute of Biotechnology and School of Chemistry, University of Manchester

mailto:[email protected]

https://twitter.com/proteincongress

https://twitter.com/proteincongress

https://twitter.com/hashtag/Proteins2018?f=tweets&src=hash

https://twitter.com/hashtag/Proteins2018?f=tweets&src=hash


2018 Proteins & Antibodies, Biosimilars & Biobetters and Peptides Congress Sponsors Include: Gold Sponsors:

Bronze Sponsors:

Congress Sponsors:



11th Annual Proteins & Antibodies Congress

Day One – 16th April 2018


07.30 – 08.20 Registration

08.20 – 08.25 Oxford Global’s Welcome Address

08.25 – 08.30 Chairperson’s Opening Address

08.30 – 09.00 Co-located Event Keynote Address: Advanced Protein Technologies To Support Discovery Reagents For Early Stage Biologics Program Ai Ching Lim, Director, Research, Amgen

Advances In Protein Engineering, Design & Selection Biotherapeutics: Manufacturing, Chemistry, Analytics And Control

09.00 – 09.30 Stream Keynote Address: Protein Engineering At Shire Angela Norton, Senior Director and Head, Protein & Antibody Engineering, Shire Pharmaceuticals

Stream Keynote Address: Innovating Bioactive Biomaterials As A Path Forward, Beyond Standard Biologics Vincent Ling, Senior Director, Takeda Pharmaceuticals

09.30 – 10.00 Solution Provider Presentation

Solution Provider Presentation

For sponsorship opportunities please contact [email protected]

10.00 – 11.20 Morning Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x3

11.20 – 11.50 GPCR Structural Biology For Drug Discovery: Through The Protein Science Lens Sujata Sharma, Director, Protein Science, Merck & Co., Inc.

Developability Profiling And Engineering Studies To Support Developability Emma Harding, Director, Head of Molecular Design and Engineering, GlaxoSmithKline

11.50 – 12.20 Improving Circulating Half-Life Of Biopharmaceuticals By Polymer Conjugation • Polymer based half-life extension technologies

• Chemical and enzymatic protein conjugation strategies

• PK/PD improvements of protein polymer conjugates

Carsten Behrens, Principal Scientist, Novo Nordisk A/S

Process Development And cGMP Manufacture Of Recombinant Botulinum Neurotoxins • Botulinum neurotoxin is effective in the treatment of several movement disorders. Native BoNT/A is

comprised of a family of highly related neurotoxins produced by Clostridium botulinum bacteria and BoNT/A (subtype A1) is notable as the strain used to produce the commercial products abobotulinumtoxinA (Dysport), onabotulinumtoxinA (Botox), and incobotulinumtoxinA (Xeomin).

• An increased understanding of the structure-function relationship of BoNT provides an opportunity to engineer recombinant (r) BoNTs with unique pharmacologic properties and therapeutic applications. This presentation will describe the construction, expression, purification, and characterization of rBoNT serotype A1 (rBoNT/A1)

• Targeted Secretion Inhibitors (TSI) are a novel class of recombinant biotherapeutic, developed by re-targeting Botulinum neurotoxins for the treatment of diseases with secretion disorders. We describe the process development and cGMP manufacture of a TSI, SXN101959, a multi-domain, multi-functional recombinant protein expressed within Escherichia coli. SXN101959 has been designed to possess a pituitary-specific site of action and to selectively inhibit growth hormone secretion from the pituitary

• During the manufacture of SXN101959, it is expressed as a single polypeptide chain and genetically engineered to contain a specific protease recognition sequence, which upon proteolytic cleavage produces the active di-chain product, held together via a disulphide bond. The SXN101959 manufacturing process has been successfully scaled up to a 200 L bioreactor scale. SXN101959 Drug Substance (DS) and liquid-formulated Drug Product (DP) were released in accordance with cGMP to supply GLP toxicology and clinical studies. An initial shelf life of one year was established for both DS and DP

Andy Hooker, Director of Pharmaceutical Sciences, Ipsen Bioinnovation Ltd










13.00 – 13.50 Lunch, Poster Presentation Sessions

13.50 – 14.20 Inhibiting Interaction Of IL17A And Its Receptor Sepideh Afshar, Principal Research Scientist, Department of Protein Engineering, Eli Lilly & Company

A Novel Serum Stability Method To Guide Engineering And Selection Of Bi-Specifics • Bi-specific domain orientation and variable region selection for optimal physical stability

• Novel in vitro screening method that predicts favorable drug-like properties

• Correlations between serum stability, in vivo PK, and biophysical properties

W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie

14.20 – 14.50 IMCgp100: A Novel TCR Based Immunotherapy Against Malignant Melanoma ImmTACTM molecules are bi-specific reagents that target tumors via a soluble monocloncal TCR with exceptionally high sensitivity and specificity and redirect host polyclonal T cells via an anti-CD3 antibody fragment. First in human studies with the lead ImmTAC, IMCgp100, show a favourable safety profile and promising signs of efficacy in both cutaneous and uveal melanoma. Development of IMCgp100 continues in uveal and cutaneous melanoma and in combination with checkpoint inhibitors.

Annelise Vuidepot, Vice President, Head of Oncology Pipeline and Research, Immunocore

Low Material Consuming, Highly Precise And Predictive Biophysical Methods For Biologics Developability Assessment • Kinetics for thermal stability

• Activation energy barrier

• Long-terms stability prediction by computational biophysical approaches

Alexey Rak, Head, BioStructure & Biophysics, Sanofi





15.20 – 16.20 Afternoon Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x3

16.20 – 16.50 Advanced Computational Tools For Protein Engineering

Yanay Ofran, Chief Executive Officer & Founder, Biolojic Design and Professor of Biophysics and Computational Biology, Bar-Ilan University

Developability Assessment Of Therapeutic Proteins – A Toolbox For Tackling Increasing Complexity • The power of an integrated approach for candidate selection, combining information from

expression and purification, physicochemical properties, solubility, stability, in vivo fitness etc.

• From platform approaches for standard molecules to project specific workpackage design for new formats

• Application of high throughput technologies enabling broad and efficient screenings for developability assessment

Thorsten Lorenz, Group Head Developability Assessment 1, Novartis









16.50 – 17.20 Engineering Cytokines With Superior Pharmacokinetic Properties: The Ligand-Receptor Fusion Approach • Using structural biology to inform fusion design

• Addressing the challenges of expression, oligomerization and glycosylation

Jon Sayers, Professor of Functional Genomics, University of Sheffield

Effect Of Project Acceleration And Breakthrough Designation On mAb Development • Front-loading versus fast to IND

• Manufacturing continuum

• Streamlining CMC package

• Minimizing upfront costs

Berthold Boedeker, Chief Scientist and Project Coordination, Bayer AG

17.20 – 17.50 Improving Protein Half-Life Extension, Potency & Selectivity Tina Møller Tagmose, Principal Scientist, Novo Nordisk A/S

Analytical Tool Box For Characterization Of Site Specific Isomerization In Monoclonal Antibodies • Isomerization

• Focused peptide mapping

• Monoclonal antibodies

Kaimeng Zhou, Analytical Team Lead, Bristol-Myers Squibb

Biotherapeutics: Manufacturing, Chemistry, Analytics And Control

17.50 – 18.20 Rapid Development Of HPLC-UV Based Multiple Quality Attributes Method

Zhi Chen, Senior Scientist, Molecular and Analytical Development, Global Manufacturing & Supply, Bristol-Myers Squibb

Supporting Robust Manufacturing With In-Depth Characterisation Of Biopharmaceutical Charge Variants • Formation of charge variants (both acidic and basic species) is inevitable during biopharmaceutical

manufacture

• The levels of these charge variants must be controlled, and their nature fully understood, for robust manufacturing of biotherapeutic products

• We show how charge variants and their formation mechanism were thoroughly characterised for the enzyme product Erwinaze®, and how this supported robust manufacture from a quality and regulatory standpoint

David Gervais, Head of Product Development, Porton Biopharma

18.20 – 18.50 Application Of Solution NMR Spectroscopy For Characterizing (And Optimizing) Formulations Of mAbs And Biopharmaceuticals • Assessing how excipients affect self-association of monoclonal antibodies (mAbs) and

other protein-based biopharmaceuticals requires informative and direct measurements which work for highly concentrated solutions in situ.

• We show that solution NMR provides a number of useful measurable parameters very sensitive to transient protein association and protein-excipient interactions in different formulations; hence it can be used as a valuable assessment tool for choosing the best formulation which minimises self-association, aggregation and liquid-liquid phase separation, as well as for assessing long-term stability, interactions with excipients, etc.

Alexander Golovanov, Senior Lecturer and Principal Investigator, Manchester Institute of Biotechnology and School of Chemistry, University of Manchester

Drug-Like-Properties Of Fully Human Antibodies Derived From Human Ig Transgenic Mice Jane Seagal, Principal Research Scientist, AbbVie





18.50 – 19.20 Think Tank Round Table Discussions Table 1 – Antibody Engineering & Evaluation Of Novel Therapeutic Candidates Moderator: W. Blaine Stine, Associate Director, Discovery Biologics, AbbVie Table 2 – Immuno-Oncology Moderator: Roy Baynes, Chief Medical Officer, Senior Vice President and Head of Global Clinical Development, MSD

• Monotherapies

• Combination therapies

• Patient selection Table 3 – Antibody Engineering, Development & Design Moderator: Stefan Weigand, Global Head of Large Molecule Research, F.Hoffmann-La Roche • Bi- and multi-specifics: what's next?

• Format follows function: biology should be driver of engineering, but where are the boundaries (complexity, CMC development, immunogenicity, ....)

• Full IgG - antibody fractions - fusion proteins: what are current trends in industry

• From binder to functional molecule: what are challenges to address increasingly complex biology

Table 4 – Cloning, Expression, Purification & Analytics Moderator: To Be Confirmed Table 5 – Protein & Antibody Biotherapeutics Moderator: To Be Confirmed

19.20 Networking Drinks & End of Day One




Day Two – 17th April 2018


08.30 – 09.00 Keynote Address: PD-1 Antibody: A Broad Spectrum Anti-Cancer Agent Both As Monotherapy And In Combination • Monotherapy activity across cancer types

• Progress in combination approaches

• Precision medicine to optimize treatment decisions

• Histology agnostic indications

Roy Baynes, Chief Medical Officer, Senior Vice President and Head of Global Clinical Development, MSD

Antibody Development, Engineering & Design Cloning, Expression, Purification & Analytics Protein & Antibody Biotherapeutics

09.00 – 09.30 Stream Keynote Address: pH Dependent Target Binding Antibodies With Altered Affinity To FcRN: An Alternate Tool To Conventional Neutralizing Antibodies • Antibodies with pH dependent binding to target antigens

and neonatal Fc receptor provide an alternative tool to conventional neutralizing antibodies

• Antibodies with a range of pH dependent target binding properties can be identified by conventional antibody generation process

• Proposed mechanism results in highly efficient clearance of soluble targets from circulation thus significantly reducing physiological concentrations of the target

Sanjaya Singh, Vice President and Head, Biotherapeutics, Johnson & Johnson

Stream Keynote Address: Integrated High Throughput Protein Purification And Analytics Kenneth Walker, Director of Research, Biologics, Amgen

Stream Keynote Address: Therapeutic Antibody Development At Teva, A Case Study • Technology platforms

• Lead antibody identification

• Mechanism of action studies

Steffen Nock, Senior Vice President (Global Biologics Head), Teva Pharmaceuticals






MAXCYTE

10.00 – 11.00 Morning Coffee & Refreshments, Poster Presentation Sessions, One to One Meetings x3

11.00 – 11.30 Developing Bispecific Antibodies For Immuno-Oncology Syd Johnson, Vice President, Antibody Engineering, Macrogenics

Recent Advancements In Protein Expression Darko Skegro, Senior Team Leader, Novartis

Antibody Biotherapeutics – Immuno-Oncology Case Study Zhulun Wang, Executive Director, Research, Amgen

















12.00 – 12.30 Engineering pH Dependent Binding Antibodies To Overcome Target Mediated Clearance In Vivo

Claire Dobson, Associate Director, Antibody Discovery and Protein Expression, MedImmune

The Salipro System For Stabilization Of Membrane Proteins • Salipro® nanoparticles allow for the reconstitution of

membrane proteins in a lipid environment: GPCRs, Transporters, Channels, Receptors

• Nanoparticles adjust to size of membrane proteins, incorporation of monomers as well as large homo/hetero-oligomeric complexes

• Technology allows to work with membrane proteins in detergent-free buffer systems

• Salipro-Membrane-Proteins enable high-resolution cryoEM, structural studies, drug screenings and generation of antibodies

Jens Frauenfeld, Chief Executive Officer, Salipro Biotech AB

Celgene Biotherapeutics Case Study From The Area Of Immuno-Oncology Hari Hariharan, Senior Director, Biotherapeutics, Celgene

12.30 – 13.30 Lunch, Poster Presentation Sessions

13.30 – 14.00 A Tale Of Two mAbs: Impacts Of The Same Unpaired Cysteines On Two Different Recombinant Monoclonal Antibodies

Yung-Hsiang Kao, Associate Director and Principal Scientist, Genentech

Innovative Platform Technologies For Antibody Detection

Patrick Garidel, Associate Director, Protein Chemistry, Boehringer Ingelheim

Roche's Approach To Discover, Design, Develop And Deliver Next Generation Protein Therapeutics Biologics have become a key component in the treatment of various life-threatening diseases. The majority of these drugs are classical monoclonal antibodies. In order to discover, design, develop and deliver differentiated, monoclonal antibodies, Roche's strategy is based on the identification of the best possible binder and engineering technologies that allow for tailored solutions for the biological problem at hand. This talk will briefly introduce Roche’s approach to next gen protein therapeutics tailored for the biological problem at hand. Concept will be explained by presenting several examples including bi-specifics for multi-pathway-inhibition, fusion proteins, and molecules designed to cross the blood-brain-barrier.

Stefan Weigand, Global Head of Large Molecule Research, F.Hoffmann-La Roche

14.00 – 14.30 TCR-Like Antibodies: Generation And Characterization • We have generated highly selective antibodies to the WT1

RMPNAPYL peptide:MHC I complex (pMHC)

• These antibodies bind pMHC with a TCR-like geometry

• We can use these antibodies to gain access to targets normally not accessible by traditional therapeutic antibodies

Michael Chin, Senior Principal Scientist and Associate Research Fellow, Pfizer

Fusion Protein Engineering And Expression Screening Ramu Sadhukhan, Principal Research Scientist, AbbVie

Biologics Research: More Better Faster Biologics are key modality for sustainable success of pharma companies. The benefit of biologics is in their high specificity, efficacy and tolerability. Sanofi is committed to becoming a leader in biologics and the company is continuously building and improving on its biologics capabilities and capacity. This presentation will discuss different elements that are relevant for building an efficient biologics research organization that delivers with high quality and on time, and satisfies internal research demands for biologics.

Katarina Radošević, Global Head Biologics Research, Sanofi R&D






14.30 – 15.00 Efficient Expression Of Multi-Chain Bispecific Antibodies In CHO Cells • Bispecific antibodies

• Expression in CHO cell

Ren Liu, Team Leader and Associate Principal Scientist, Merck & Co., Inc.

Genetic Engineering Of CHO Cells – Site Specific Manipulation And Targeted Integration Christian Bernloehr, Project Leader, Molecular Biology Department, Boehringer Ingelheim

Specific Immune Response To PLBL2, A Host Cell Impurity In Clinical Material A product related impurity was identified in the material used in clinical study. To assess the potential ability of patients to develop an immune response to the impurity and impact on immunogenicity of the therapeutic two bridging ELISA were developed and validated. Samples from treated subjects were evaluated in both assays. This presentation will discuss the results of the immunogenicity assessment to the impurity and observed immunogenicity rate of the antibody therapeutic.

Sally Fischer, Principal Scientist and Group Leader, Genentech

15.00 – 15.30 Afternoon Coffee & Refreshments, Poster Presentation Sessions

15.30 – 16.00 Engineering Of Highly Selective Anti-Aβ42 Antibody With Picomolar Affinity For The Treatment Of Alzheimer’s Disease • MEDI1814 is a novel, highly potent and selective inhibitor

of the most neurotoxic forms of the amyloid beta peptide, Aβx-42, whilst sparing the non-toxic forms of Aβ40

• The antibody engineering, in vitro characterisation and pre-clinical in vivo evaluation will be presented

Christopher Lloyds, Senior Scientist, Senior Scientist, Protein Engineering, MedImmune

Latest Developments On MicroRNAs For Next-Generation Cell Engineering MicroRNAs constitute an important class of non-coding RNAs. Individual miRNAs control entire bioprocess relevant cellular pathways and thus receive growing attention in biotechnology. Our comprehensive miRNA research in a variety of production cell lines with different genetic backgrounds led to the generation of a ‘miRNA target catalog’ providing an avenue for next-generation CHO cell engineering.

Kerstin Otte, Professor, University of Applied Sciences Biberach

Novel Monoclonal Antibody Therapies For Serious Infections • Antibodies, including monoclonal antibodies have a rich

history of therapeutic success, but only recently have mAbs been applied to serious infectious diseases

• mAbs have unique features that make them particularly suited to the modern challenges of infections, including the rapid, global emergence of antimicrobial resistance

• Targeted mAbs can be used to pre-empt disease, and current mAb discovery and development approaches overcome the traditional concerns over the use of biologics as anti-infectives

• Specific examples of challenges and opportunities will be reviewed, along with select data to demonstrate the great potential of mAbs to treat and prevent serious infections

David Mantus, Chief Development Officer, Arsanis

Antibody Development, Engineering & Design Protein & Antibody Biotherapeutics

16.00 – 16.30 Developability Assessments For Selection Of Final Candidates • An overview of the developability assessment of pre-clinical candidates at Janssen will be given at the presentation

• The characterization of the NIST IgG1 material will be described in the presentation

• Two Specific case studies with a focus in the assessment of bispecific candidates will be included in the presentation

Dorina Saro, Senior Research Scientist, Johnson & Johnson

Chlorotoxin In Peptide Drug Conjugates: MoA Studies Identify Its True Tumor Target • Chlorotoxin is a tumor targeting peptide that naturally

occurs in scorpion venom; as a radio-labeled peptide it proved efficacious in human glioma clinical trials

• Peptide Drug Conjugate (PDC) with chlorotoxin to target tumors and cryptophycin as warhead has a promising pharmacological profile preclinically

• Several proposed targets previously described for chlorotoxin do not align with the observed PDC activity

• Comprehensive analysis of MoA of chlorotoxin reveals its true target which is distinct and separate from its toxic properties in venom

Sharon McGonigle, Senior Principal Scientist, Eisai





Protein & Antibody Biotherapeutics

16.30 – 17.00 Development Of An Integrated Novel Antibody Discovery Platform Using Single B Cell Technologies • Discovery of therapeutic monoclonal antibodies by using proprietary B cell technology platform.

• The integrated novel antibody discovery platform enables high throughput and efficient discovery and generation of fully human therapeutic antibodies from antigen specific single B cells.

• Integration of single cell next-generation sequencing in the antibody discovery process facilitates discovery of broader and diverse antibody repertoire.

Pallavi Tawde, Single B Cell Cloning Platform Leader, Bristol-Myers Squibb

17.00 – 17.30 Targeting Immune Checkpoints – An F-Star Case Study Michelle Morrow, Director, Preclinical Translational Pharmacology, F-Star Biotechnology

17.30 End of Conference



Conference: 16-17 April 2018 London UK www.proteins-congress.com

HOW TO REGISTER:

FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: [email protected]

Please complete fully and clearly. Please photocopy for additional delegates Title:_____Forename:_______________Surname:________________ Job Title:_________________________________________________ Company/Organisation:_____________________________________ Email:___________________________________________________ Address:_________________________________________________ ________________________________________________________ Postcode: ____________________ Country: ___________________ Direct Telephone ________________ Direct Fax: ________________ Mobile: ________________________ Switchboard: _____________ Signature: ______________________ Date: _____________________

Number of delegates:

Industry del(s) Academic dels(s) Vendor dels(s) Special Offer: 3 for 2

Offer is only valid on the congress and for those registering at Industry or Academic rates

CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number:

Valid from: / Expiry Date: /

Security code:

Cardholders name: _______________________________________

Signature: ______________________________ Date: ___________

PLEASE INVOICE ME:

Invoice Address (if different from above)_______________________

*Please note there is a £50 plus VAT handling charge for payment via invoice *All card payments will be subject to a 3% bank charge or 4% AMEX charge

Registration Fees

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to pay-ments settled online. Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility. Poster Presentations Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size. Cancellation and Curtailment Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation. More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee/ 25% refund Less than 3 months prior to the event Full cancellation fee / No refund Data Protection The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein. Miscellaneous This Agreement may not be transferred or assigned by either the Delegate or the Delegate’s Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.

I agree to the above Terms and Conditions

How to Pay (choose one of the following payment options)

I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies)

Congress £799 plus VAT

1 day pass £499 plus VAT

Day 1 Day 2

Academic Delegates

Congress £499 plus VAT 1 day pass £299 plus VAT Day 1 Day 2

Vendor Delegates (CROs, Consultants, Technology and Service Providers)

Congress Only £1750 plus VAT 1 day pass £999 plus VAT Day 1 Day 2

Poster Presentation £250 plus VAT

PROMOTIONAL LITERATURE DISTRIBUTION

Distribution of your company’s promotional literature to all conference attendees £999 plus VAT

Documentation

I cannot attend but would like to purchase access to the following:

Access to the online conference presentations £499 plus VAT Conference presentations - paper copy £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]

Terms & Conditions of Booking

Delegate Details

2018 speakers include… - proteins congress · • jens frauenfeld, chief executive officer,...

Documents